Although the exact reason why FASN expression negatively correlates with sensitivity to endocrine therapy in ER+/HER2+ breast carcinomas needs to be explored in depth, it is clear that that the mechanisms regulating FASN expression notably differ between molecularly distinct luminal A and luminal B-like breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.